Solutions

• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery

Myeloid-enhanced Humanized Mice Development Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The Necessary of Developing Myeloid-enhanced Humanized Mice

Humanized mouse models show great promise as pre-clinical research models for CAR-T evaluations. At present, several studies have been undertaken to address the present restrictions associated with the inclusion of humanized mice, which aim to enhance the myeloid in humanized mouse models for more comprehensive human immune system restoration. Based on this, it is urgent to develop a myeloid-enhanced humanized mouse model to prompt the applications of CART therapy and other immunotherapies in clinical.

Fig. 1 CAR T cell evaluation using patient-derived xenograft mice.¹

Our Myeloid-enhanced Humanized Mice for CART In Vivo Testing: Efficient! Convenient! Trustworthy!

Creative Biolabs developed a series of myeloid-enhanced humanized mice for CART in vivo testing. We provide ready-to-use myeloid-enhanced humanized mice models featuring more complete immune reconstitutions for customers to choose from. Furthermore, we provide several delivery methods to introduce the target gene into immunodeficient mouse models (NOD-SCID mice, NSG mice, NOG mice, etc.) for more complete human immune system reconstitution. Noteworthy, if you want to introduce the desirable targets to construct specific humanized mice, we are confident to customize our service to meet your needs. By working with our myeloid-enhanced humanized mice, we guarantee that you will be able to confirm results more conveniently.

Fig. 2 Humanized mouse models are being used to evaluate current immunotherapies in cancer research.²

Hot Targets

Here we provide several hot targets to choose from for your projects:

• NSG-SGM3

A myeloid-enhanced humanized mouse model that is genetically modified to express human interleukin-3, GM-CSF, and SF on the NSG mouse background. The number of human myeloid cells and human CD4⁺ Treg cells in the NSG-SGM3 mouse increases. The mouse model has great application potential in detecting cytokine storms caused by CAR-T and supporting the reconstruction of CAR-Mac cells in vivo.

• NOG-EXL

A myeloid-enhanced humanized mouse model was obtained by introducing human cytokines IL-3 and GM-CSF based on NOG. huNOG-EXL is currently the most complete animal model for the reconstruction of the human immune system. It can be used to verify the anti-tumor effect of PD1 antibodies and also supports the validation of drug efficacy in the acute myeloid leukocyte (AML) PDX model.

• MISTRG

A myeloid-enhanced humanized mouse model equipped with a BAC transgenic that encodes human SIRPα. It reduces the phagocytosis of human CD47-expressing cells, which allows for extremely lenient human hematopoiesis.

Important Applications

• Drug Discovery Models;
• Drug Repurposing Using Humanized Mice;
• Exploring Novel Mechanisms of Resistance and Disease;
• Biomarker Identification of ICIs to Enhance the Predictability of Drug Reactions.

As a leader in the field, Creative Biolabs focused on improving the existing technologies and creating novel technologies to aid in the development of cancer therapy. If you want to know more about our myeloid-enhanced humanized mice for CART in vivo testing, please get in touch with us.

References

1. Mhaidly, Rana, and Els Verhoeyen. "Humanized mice are precious tools for preclinical evaluation of CAR T and CAR NK cell therapies." Cancers 12.7 (2020): 1915.
2. Karnik, Isha, et al. "Emerging Preclinical Applications of Humanized Mouse Models in the Discovery and Validation of Novel Immunotherapeutics and Their Mechanisms of Action for Improved Cancer Treatment." Pharmaceutics 15.6 (2023): 1600.